Autopsy report · NCT01535092

Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients

“when realized that the target 60% of patients with SVR was no more achievable”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months after it had already started.
• Ran for about 1 year 2 months before it stopped.
• 14 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Rottapharm

Sponsor type

Industry

Conditions

HCV Recurrence After Liver Transplantation

Interventions

Silibinin; Placebo

Participants

14

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.